Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (362)	3/30/1998 11:47:00 AM
From: Dave Dalry	Read Replies (3) \| Respond to of 2887

People this thread is starting to sound like others I have been involved with.. Everyone predicting huge gains, cars they will buy etc.. This stock is only at .66 and has a long way to go. We don't want to be accused of hyping do we? Dave P.S. I bought some more today at .66, less than thirty seconds later the bid drops.. Typical..

To: Jeffrey L. Henken who wrote (362)	3/30/1998 8:02:00 PM
From: Aishwarya	Respond to of 2887

Here are a couple of tid bits reflecting analyst mentality on a couple of companies ie. JNJ and Boston scientific. *******Forbes :*** INVESTORS have taken a fancy to Boston Scientific Corp. (NYSE: BSX), a $1.5 billion maker of minimally invasive medical devices. The shares trade at over 53 times last year's earnings. Justification: a history of 35% earnings growth. Those days are over: Boston's earnings growth will slow to 25% this year. Why? A $300 million upgrade of five factories and efforts integrating almost a dozen acquisitions made in the past two years. Worse, Boston's biggest business is becoming a commodity. Balloons for angioplasty make up an estimated 45% of sales, but surgeons now prefer balloons with stents attached-devices that keep arteries open-a combination Boston sells in Europe but not in the U.S. Johnson & Johnson does; it sells angioplasty balloons and coronary stents together. Even if Boston gets into the U.S. market with a combination of its own, market leader J&J will be ahead in winning over customers. Another competitor-Medtronic-won approval for its stent last month. Though Boston expects big sales from Europe, analysts aren't sure. Less red tape overseas means more competitors-more than 20. Some offer free samples, others sell cheaper versions. Disappointing results in April sent Boston's stock down 33%, but it recovered quickly. More disappointments could easily push the shares down to 45, a loss of about one-third its current value. If you want to short the stock, the company's 111 million shares are borrowable. ***The Fools board:********** Johnson & Johnson (NYSE: JNJ) (N) (S) operates in three segments: consumer products, medical devices, and professional products. The pharmaceuticals division accounts for about a third of the company's revenues but produces around 60% of the company's profits. With over 22 compounds slated to hit the market in the next two years and no major drugs going off patent until 1999, J&J is well positioned in the ethical drug segment. The company is the largest manufacturer of health care products in the world, with such strong brand names as Band-Aid and Tylenol. J&J markets numerous medical devices, the most controversial of which is the Palmaz-Schatz stent, which has dominant market share in the stent market in the U.S. The release of strong competitive products from Guidant and Boston Scientific has many concluding that J&J's market dominance in this segment is set for decline. Valued at 24x forward earnings J&J is certainly not undervalued, but it is actually the most palatable stock in a group that is dominated by 52 week highs. It is important to remember that stents represent less than 4% of J&J's corporate revenues despite their high margins. With all of these companies at the high end of their valuations, this momentary lukewarm feeling toward J&J presents an opportunity to acquire a company that may not excel in the short term but will continue to perform for decades. *Inspite of the fact that stents represent less than 4% of J&J's corporate revenues, they do not want their prescence to diminish in these areas as these areas will grow by leaps and bounds as the world population is increasing astronomically every year. Also it makes perfect business sense to have a heavy hand in every pot as they can afford to do so and stay big and powerful ********** Regards, Sri.